Fig. 5.

Receiver operating characteristic (ROC) curves for the differentiation of chemotherapy+trastuzumab (C+T) or trastuzumab monotherapy (T) B and NB cases using histological scores from poly-ligand profiling (PLP) with libraries EL-NB and EL-B in the test set of 61 cases. a ROC curve obtained based on EL-NB library PLP scores. AUC 0.73, p = 0.01. b ROC curve obtained based on EL-B library PLP scores. AUC 0.63, p = 0.11. c ROC curves obtained based on combined PLP scores of EL-NB and EL-B libraries using a logistic regression algorithm (blue curve, AUC = 0.81, p = 0.0007); black dashed curve: 10-fold cross-validation on the combined scores of EL-NB and EL-B libraries (AUC = 0.78, p = 0.002), 10-fold cross-validation was run 100 times and the average predictive score was used as the final cross-validation result; red curve: AUC values obtained by HER2-IHC scoring of the same 61 cases (AUC = 0.47); purple dashed curve: performance of the combined libraries on 63 HER2 cases independent from the test set who received platinum/taxane combination therapy instead of trastuzumab (AUC = 0.53). TTNT data for these patients are unrelated to trastuzumab-based regimens